Akiko Sato1,2, Motoko Omura3, Yumiko Minagawa3, Kengo Matsui3, Ryosuke Shirata3, Hideyuki Hongo3, Harumitsu Hashimoto4, Toshihiro Misumi5, Tomio Inoue6, Masaharu Hata2. 1. Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan akikosato.tk@gmail.com. 2. Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 3. Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan. 4. Department of Radiation Oncology, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan. 5. Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan. 6. Department of Advanced Medical Center, Shonan Kamakura General Hospital, Kamakura, Japan.
Abstract
BACKGROUND/AIM: This study aimed to evaluate the effect of intensity-modulated radiation therapy (IMRT) on the clinical outcomes of patients with lymph node (LN) oligo-recurrence and a controlled primary tumor. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 21 patients diagnosed with LN oligo-recurrence who received IMRT with curative intent. Patients with tumor of various primary sites and histopathological types were included in this study. RESULTS: The 3-year overall survival (OS) and in-field progression-free survival (PFS) rates were 75% and 52%, respectively. Statistical analysis showed that lower dose to the gross tumor volume (GTV) and larger GTV were significantly associated with poorer OS; adenocarcinoma and lower dose to GTV were significantly associated with poorer in-field PFS. No patients experienced severe adverse events. CONCLUSION: IMRT may provide a safe and effective treatment for patients with LN oligo-recurrence. Tumor dose-escalation sparing normal tissue using IMRT technology may improve the OS and in-field PFS. Copyright
BACKGROUND/AIM: This study aimed to evaluate the effect of intensity-modulated radiation therapy (IMRT) on the clinical outcomes of patients with lymph node (LN) oligo-recurrence and a controlled primary tumor. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 21 patients diagnosed with LN oligo-recurrence who received IMRT with curative intent. Patients with tumor of various primary sites and histopathological types were included in this study. RESULTS: The 3-year overall survival (OS) and in-field progression-free survival (PFS) rates were 75% and 52%, respectively. Statistical analysis showed that lower dose to the gross tumor volume (GTV) and larger GTV were significantly associated with poorer OS; adenocarcinoma and lower dose to GTV were significantly associated with poorer in-field PFS. No patients experienced severe adverse events. CONCLUSION: IMRT may provide a safe and effective treatment for patients with LN oligo-recurrence. Tumor dose-escalation sparing normal tissue using IMRT technology may improve the OS and in-field PFS. Copyright
Authors: Sun Hyun Bae; Mi-Sook Kim; Chul Koo Cho; Jin-Kyu Kang; Hye Jin Kang; Young Han Kim; Ui-Sup Shin; Sun Mi Moon; Dong Han Lee Journal: J Surg Oncol Date: 2012-02-01 Impact factor: 3.454
Authors: A J Conde-Moreno; J L Lopez-Guerra; V A Macias; M L Vázquez de la Torre; P Samper Ots; S San José-Maderuelo; J Pastor Peidro; J López-Torrecilla; J Expósito-Hernández Journal: Clin Transl Oncol Date: 2015-09-02 Impact factor: 3.405
Authors: Mi-Sook Kim; Sung Yul Yoo; Chul Koo Cho; Hyung Jun Yoo; Kwang Mo Yang; Jin Kyu Kang; Dong Han Lee; Jong Inn Lee; Ho Youn Bang; Min Suk Kim; Hae Jin Kang Journal: J Korean Med Sci Date: 2009-06-16 Impact factor: 2.153